Security key
45719W205
Inhibikase Therapeutics, Inc. - Common Stock, $0.001 par value (IKT)
CUSIP: 45719W205
Q2 2025 13F Holders as of 30 Jun 2025
- Type / Class
- Equity / Common Stock, $0.001 par value
- Shares outstanding
- 140,000,283
- Total 13F shares
- 54,512,097
- Share change
- +3,040,159
- Total reported value
- $106,299,597
- Price per share
- $1.95
- Number of holders
- 48
- Value change
- +$5,482,917
- Number of buys
- 34
- Number of sells
- 29
Report period
Q2 2025
Institutions
48
Top holders
10
IKT full security history
Newer quarter: Q3 2025
Previous quarter: Q1 2025
Inhibikase Therapeutics, Inc. SEC filings
Inhibikase Therapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 45719W205
Recent filing periods:
Top shareholders of IKT - Inhibikase Therapeutics, Inc. - Common Stock, $0.001 par value (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Sands Capital Alternatives, LLC |
13F
|
Company |
7.8%
|
10,950,000
|
$23,980,500 | — | 31 Mar 2025 | |
| Soleus Capital Management, L.P. |
13F
|
Company |
4.5%
|
6,325,000
|
$13,851,750 | — | 31 Mar 2025 | |
| Fairmount Funds Management LLC |
13F
|
Company |
4.4%
|
6,125,000
|
$13,413,750 | — | 31 Mar 2025 | |
| PERCEPTIVE ADVISORS LLC |
13F
|
Company |
4.2%
|
5,925,000
|
$12,975,750 | — | 31 Mar 2025 | |
| Commodore Capital LP |
13F
|
Company |
3.8%
|
5,344,432
|
$11,704,306 | — | 31 Mar 2025 | |
| ADAR1 Capital Management, LLC |
13F
|
Company |
3.7%
|
5,122,105
|
$11,217,410 | — | 31 Mar 2025 | |
| ARMISTICE CAPITAL, LLC |
13D/G
|
— |
5%
|
3,529,006
|
$7,975,554 | $0 | 31 Dec 2024 | |
| VANGUARD GROUP INC |
13F
|
Company |
2%
|
2,848,663
|
$6,238,572 | — | 31 Mar 2025 | |
| Nantahala Capital Management, LLC |
13F
|
Company |
1.6%
|
2,190,000
|
$4,796,100 | — | 31 Mar 2025 | |
| Blackstone Inc. |
13F
|
Company |
1.5%
|
2,070,684
|
$4,534,798 | — | 31 Mar 2025 | |
| Stonepine Capital Management, LLC |
13F
|
Company |
0.65%
|
914,973
|
$2,003,791 | — | 31 Mar 2025 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.65%
|
913,502
|
$2,000,569 | — | 31 Mar 2025 | |
| Roberto Bellini |
3/4/5
|
Director |
—
mixed-class rows
|
1,568,176
mixed-class rows
|
$2,000,200 | — | 30 Jun 2025 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
0.36%
|
504,625
|
$1,105,129 | — | 31 Mar 2025 | |
| BlackRock, Inc. |
13F
|
Company |
0.3%
|
423,979
|
$928,514 | — | 31 Mar 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.23%
|
324,760
|
$711,285 | — | 31 Mar 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.12%
|
166,025
|
$363,595 | — | 31 Mar 2025 | |
| BLAIR WILLIAM & CO/IL |
13F
|
Company |
0.11%
|
155,953
|
$341,537 | — | 31 Mar 2025 | |
| MARSHALL WACE, LLP |
13F
|
Company |
0.11%
|
155,270
|
$340,041 | — | 31 Mar 2025 | |
| JANE STREET GROUP, LLC |
13F
|
Company |
0.08%
|
116,249
|
$254,585 | — | 31 Mar 2025 | |
| Arvind Kush |
3/4/5
|
Director |
—
mixed-class rows
|
253,176
mixed-class rows
|
$198,650 | — | 30 Jun 2025 | |
| BARCLAYS PLC |
13F
|
Company |
0.06%
|
84,000
|
$183,960 | — | 31 Mar 2025 | |
| BALYASNY ASSET MANAGEMENT L.P. |
13F
|
Company |
0.06%
|
81,161
|
$177,743 | — | 31 Mar 2025 | |
| HRT FINANCIAL LP |
13F
|
Company |
0.05%
|
65,906
|
$144,000 | — | 31 Mar 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.05%
|
64,011
|
$140,184 | — | 31 Mar 2025 | |
| OMERS ADMINISTRATION Corp |
13F
|
Company |
0.04%
|
56,000
|
$122,640 | — | 31 Mar 2025 | |
| Jain Global LLC |
13F
|
Company |
0.04%
|
54,845
|
$120,111 | — | 31 Mar 2025 | |
| UBS Group AG |
13F
|
Company |
0.03%
|
45,266
|
$99,133 | — | 31 Mar 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.03%
|
45,026
|
$98,607 | — | 31 Mar 2025 | |
| STATE STREET CORP |
13F
|
Company |
0.03%
|
41,884
|
$91,726 | — | 31 Mar 2025 | |
| Qube Research & Technologies Ltd |
13F
|
Company |
0.03%
|
35,625
|
$78,019 | — | 31 Mar 2025 | |
| ExodusPoint Capital Management, LP |
13F
|
Company |
0.02%
|
32,538
|
$71,000 | — | 31 Mar 2025 | |
| LMR Partners LLP |
13F
|
Company |
0.02%
|
31,092
|
$68,091 | — | 31 Mar 2025 | |
| Diametric Capital, LP |
13F
|
Company |
0.02%
|
28,366
|
$62,121 | — | 31 Mar 2025 | |
| Y-Intercept (Hong Kong) Ltd |
13F
|
Company |
0.02%
|
26,775
|
$58,637 | — | 31 Mar 2025 | |
| CITIGROUP INC |
13F
|
Company |
0.02%
|
25,765
|
$56,425 | — | 31 Mar 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0.02%
|
21,646
|
$47,405 | — | 31 Mar 2025 | |
| Joseph Frattaroli |
3/4/5
|
Cheif Financial Officer |
—
mixed-class rows
|
138,091
mixed-class rows
|
$38,473 | — | 01 Mar 2023 | |
| Schonfeld Strategic Advisors LLC |
13F
|
Company |
0.01%
|
16,876
|
$36,958 | — | 31 Mar 2025 | |
| CAXTON CORP |
13F
|
Company |
0.01%
|
16,393
|
$35,901 | — | 31 Mar 2025 | |
| Point72 Asia (Singapore) Pte. Ltd. |
13F
|
Company |
0.01%
|
14,976
|
$32,797 | — | 31 Mar 2025 | |
| Jefferies Financial Group Inc. |
13F
|
Company |
0.01%
|
14,800
|
$32,412 | — | 31 Mar 2025 | |
| Catalyst Funds Management Pty Ltd |
13F
|
Company |
0.01%
|
13,712
|
$30,029 | — | 31 Mar 2025 | |
| STIFEL FINANCIAL CORP |
13F
|
Company |
0.01%
|
13,129
|
$28,751 | — | 31 Mar 2025 | |
| Quantessence Capital LLC |
13F
|
Company |
0.01%
|
13,005
|
$28,481 | — | 31 Mar 2025 | |
| PRELUDE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.01%
|
11,098
|
$24,305 | — | 31 Mar 2025 | |
| CAPSTONE INVESTMENT ADVISORS, LLC |
13F
|
Company |
0.01%
|
11,067
|
$24,237 | — | 31 Mar 2025 | |
| Brevan Howard Capital Management LP |
13F
|
Company |
0.01%
|
10,384
|
$22,741 | — | 31 Mar 2025 | |
| Cubist Systematic Strategies, LLC |
13F
|
Company |
0.01%
|
9,043
|
$19,804 | — | 31 Mar 2025 | |
| Point72 (DIFC) Ltd |
13F
|
Company |
0%
|
1,980
|
$4,336 | — | 31 Mar 2025 |
Institutional Holders of Inhibikase Therapeutics, Inc. - Common Stock, $0.001 par value (IKT) as of Q2 2025
As of 30 Jun 2025,
Inhibikase Therapeutics, Inc. - Common Stock, $0.001 par value (IKT) was held by
48 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
54,512,097 shares.
The largest 10 holders included
Sands Capital Alternatives, LLC, Soleus Capital Management, L.P., Fairmount Funds Management LLC, PERCEPTIVE ADVISORS LLC, Commodore Capital LP, ADAR1 Capital Management, LLC, VANGUARD GROUP INC, BlackRock, Inc., Blackstone Inc., and Nantahala Capital Management, LLC.
This page lists
48
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2025 vs Q1 2025 Across Filers
Q1 2025 holders
47
Q2 2025 holders
48
Holder diff
1
| Investor | Q1 2025 Shares | Q2 2025 Shares | Share Diff | Share Chg % | Q1 2025 Value $ | Q2 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.